Our previous study demonstrated that EGFR mutation was detected in ~18% of patients with PPC, especially those with an adenocarcinomatous component; however, in those with a sarcomatoid component, KRAS mutations were not observed in all patients [5]. This evidence concerns the gene KRAS and primary peritoneal carcinoma.